Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data MapLight Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
68.5
138
General and administrative
14.4
30.7
Operating expenses
82.9
169
Operating income
-82.9
-169
Interest income
4.5
5.52
Other non-operating income
5.37
7.93
Net income
-77.6
-161
EBITDA
-82.2
-169
EPS, basic
-105.38
-18.56
EPS, diluted
-105.38
-18.56
Shares, basic (weighted)
0.74
8.68
Shares, diluted (weighted)
0.74
8.68
Balance sheet
FY2025
FY2025
Cash and equivalents
38.3
46.7
Short-term investments
70.5
258
Other current assets
5.81
19.6
Total current assets
115
325
Property, plant and equipment
1.21
1.1
Lease right-of-use assets
6.35
5.49
Long-term investments
11.4
148
Other non-current assets
3.17
0.06
Total assets
137
480
Accounts payable
1.91
3.29
Accrued liabilities
9.99
12
Deferred revenue
3.24
0
Total current liabilities
15.9
16.2
Lease liabilities
5.8
4.91
Total liabilities
21.7
21.1
Paid-in capital
5.58
819
Retained earnings
-199
-361
Other comprehensive income
0.16
-0.23
Shareholders' equity
-194
458
Total equity
-194
458
Total liabilities and equity
137
480
Shares outstanding
0.76
44
Cash flow statement
FY2025
FY2025
Net income
-77.6
-161
Depreciation and amortization
0.7
0.58
Stock-based compensation
1.08
36
Change in payables
-1.35
1.38
Cash from operations
-78.8
-138
Capital expenditures
-0.77
-0.47
Purchases of investments
-125
-408
Sales and maturities of investments
45
85.5
Cash from investing
-80.8
-323
Stock issued
0.29
0.29
Cash from financing
118
470
Net change in cash
-41.5
8.48
Free cash flow
-79.6
-139
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.46 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-66.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-62.4%
Net income / average total assets.
Return on invested capital (ROIC)
-69.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
250.2%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
1,079.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
16.5x
Current assets / current liabilities.
Quick ratio
15.8x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
15.8x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$3.85
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.84
Cash from operations / diluted weighted shares.
Book value per share
$7.67
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.31x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.31x
Market cap / tangible book value, when positive.
FCF yield
-38.4%
Free cash flow / market cap.
Earnings yield
-50.3%
Net income / market cap (the inverse of P/E).
Was MapLight Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $161.2M.
How much free cash flow did MapLight Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $138.1M minus capital expenditures of $473.0K left free cash flow of -$138.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.